Sangamo’s ART-less Approach In HIV Painting A Nice Picture
This article was originally published in Pharmaceutical Approvals Monthly
Company shows it’s possible to achieve functional control of HIV with SB-728T after stopping antiretroviral therapy. But the “Berlin”-inspired genetic approach still needs to generate more data before the firms feels it can start partnering talks in earnest.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.